CandlesenseCandlesense
NKTR•benzinga•

Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflam

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 18, 2024 by benzinga

← Back to NKTR News
    Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflam | NKTR Stock News | Candlesense